Formulary Management Meets Patent Strategy: The Complete LCM Playbook for Pharma IP Teams
Drug patent expiration doesn’t always mean generics enter the market right away. Many factors affect generic drug launches and drug formulary changes.
Drug Patent Expiration Playbook: Protect Revenue, Defend IP, and Outlast the Cliff
There’s no reason to assume that every branded drug will fall victim to the “patent cliff.” Actions taken before drug patent expiration can extend drug life cycles.
Drug Patent Expiration Playbook: Protect Revenue, Defend IP, and Outlast the Cliff Read Post »
AI Drug Patent Strategy: How Artificial Intelligence Is Reshaping Pharmaceutical IP Portfolios, Prior Art, and Patent Litigation
Artificial intelligence is allowing chemists to find new way to synthesize drug molecules, and forcing drug developers to shore up their patent strategies.
Drug Patent Evergreening Works, Until It Doesn’t: How drug makers extend patent life, what the evidence says about generic delay, and where the system is finally breaking down
There is a question that gets debated in congressional hearings, litigated in federal courts, and studied in academic journals with
505(b)(2) NDAs: The Complete IP, Litigation, and Commercial Strategy Guide for 2025
943 drugs approved. $15M to $100M in development costs versus $2.6B for an NCE. One regulatory mechanism sits at the
505(b)(2) NDAs: The Complete IP, Litigation, and Commercial Strategy Guide for 2025 Read Post »
Drug Sales Data: The Complete Playbook for Channel Strategy and Portfolio Dominance
1. What Pharmaceutical Sales Data Actually Measures Pharmaceutical sales data is not a single dataset. It is a composite of
Drug Sales Data: The Complete Playbook for Channel Strategy and Portfolio Dominance Read Post »
Generic Entry Pricing: The Complete Drug Price Data Playbook for Portfolio Managers
How to use price erosion curves, Paragraph IV filings, Orange Book patent analysis, and biosimilar IP valuation to build a
Generic Entry Pricing: The Complete Drug Price Data Playbook for Portfolio Managers Read Post »
Generic Drug Patent Law: The Complete Playbook for Market Entry, FDA Strategy, and Competitive Intelligence
Generic drugs account for nearly 90% of all prescriptions dispensed in the United States yet represent only about 20% of
DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions
DrugPatentWatch, a provider of global biopharmaceutical business intelligence, has entered into a partnership with Adis. The partner will enhance Adis’
DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions Read Post »
